The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

February 14, 2023

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

February 14, 2023

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

February 14, 2023

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

February 13, 2023

Drs Short and Reagan discuss risk factors that can contribute to patients’ likelihood of developing tumor lysis syndrome, preventive measures for patients most at risk, and the clinical implications of standard treatment options for patients with tumor lysis syndrome.

February 13, 2023

Kyle A. Blum, MD, MS, says that results from a study of patients renal medullary carcinoma suggest that with CA-125, an established biomarker for ovarian cancer, may play a similar role in this rare disease.

February 13, 2023

Kyle A. Blum, MD, MS, says that patients with renal medullary carcinoma have poor prognosis, but anecdotal evidence suggests that survival outcomes may be improving.

February 13, 2023

Kyle A. Blum, MD, MS, discusses how few physicians have experience with renal medullary carcinoma, and the disease often presents with nonspecific symptoms.

February 13, 2023

Kyle A. Blum, MD, MS, explains how renal medullary cancer, like most rare cancers, can be difficult to study. However, there are several ongoing studies that include this patient population.

February 10, 2023

Scott Kopetz, MD, discussed the key objectives of the phase 3 BREAKWATER trial being done in patients with BRAF V600E–mutated mCRC, the recently reported safety and efficacy data observed with encorafenib plus cetuximab and chemotherapy, and the importance of conducting biomarker research to further personalize treatment in these patients.

February 09, 2023

Experts in metastatic colorectal cancer management highlight the role of molecular testing and testing modalities available in the academic and community settings.

February 02, 2023

Naveen Pemmaraju, MD, highlights unmet needs in the setting of myelofibrosis management and looks toward future evolutions in the treatment paradigm.

February 02, 2023

Expert perspectives on specific subsets of the REFINE study, which combined ruxolitinib with navitoclax in patients diagnosed with myelofibrosis.

February 02, 2023

Shifting his focus to treatment strategies in myelofibrosis, Naveen Pemmaraju, MD, reviews the current drug armamentarium and explains how it ties into disease modification.

February 02, 2023

Expert hematologist-oncologist Naveen Pemmaraju, MD, highlights current strategies in diagnosing and stratifying patients with myelofibrosis.

January 31, 2023

Mariana Chavez Mac Gregor, MD, MSC, discusses key efficacy and safety data from the phase 3 SWOG S1207 trial of everolimus in hormone receptor–positive, HER2-negative breast cancer.

January 31, 2023

Michael L. Wang, MD, discusses the efficacy of the noncovalent BTK inhibitor pirtobrutinib, as well as safety data from the phase 1/2 BRUIN trial in mantle cell lymphoma.

January 30, 2023

Van K. Morris, MD, discusses the evaluation of circulating tumor as a predictive biomarker for the use of adjuvant chemotherapy in patients with low-risk, stage II colon cancer.

January 26, 2023

Shubham Pant, MD, discusses the rationale, trial design, and key efficacy and safety data from an expansion cohort of the phase 2 RAGNAR trial in biliary tract cancers.

January 16, 2023

Axicabtagene ciloleucel continued to elicit improved progression-free survival and overall response rates in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

January 09, 2023

Sapna Patel, BA, MD, discusses the sequencing of immunotherapy and targeted therapy in BRAF-mutant melanoma.